Welcome to our dedicated page for Neuraxis SEC filings (Ticker: NRXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the next clinical milestone or spotting executive share purchases inside Neuraxis Inc’s disclosures can feel like searching for a needle in a 300-page haystack. Investors typically dive into a Neuraxis quarterly earnings report 10-Q filing for cash-burn details, or scan Neuraxis insider trading Form 4 transactions for clues ahead of pivotal trial data. That user journey starts here.
Stock Titan’s platform turns dense documents into clear insights. Our AI reads every line so you don’t have to, delivering Neuraxis SEC filings explained simply within minutes of hitting EDGAR. Need the footnotes on R&D spend? Click the AI summary under Neuraxis annual report 10-K simplified. Want alerts the second insiders move? Real-time push updates flag Neuraxis Form 4 insider transactions real-time. We also map terminology—PENFS, IB-Stim, FDA clearances—so you’re never lost while understanding Neuraxis SEC documents with AI.
Every filing type is covered in one place:
- 8-K clinical updates with Neuraxis 8-K material events explained
- Proxy materials for Neuraxis proxy statement executive compensation
- Detailed cash-flow trends via Neuraxis earnings report filing analysis
- Instant alerts on Neuraxis executive stock transactions Form 4
Whether you’re monitoring FDA timelines, gauging burn rate, or tracking insider confidence, our AI-powered summaries, expert commentary, and real-time feeds ensure you act on complete information—not on assumptions. Explore every Neuraxis disclosure the moment it lands and transform complex neuromodulation filings into actionable clarity.
Masimo Corp, identified as a 10% beneficial owner of Neuraxis, Inc. (NRXS), filed a Form 4 disclosing a complete exit from its common-stock position on 1 July 2025.
- Common-stock sales: 531,548 shares sold at $2.25 per share (Code S); beneficial ownership after this trade: 0 shares.
- Pre-funded warrant conversion: 289,779 shares acquired via automatic warrant exercise at $0.0001 per share (Code C), immediately followed by the sale of the same 289,779 shares at $2.25 per share (Code S).
- Derivative position: The pre-funded warrant (exercise price $0.0005) was fully exercised/converted (Code M) and now shows 0 derivative securities outstanding.
Net result: Masimo liquidated a total of 821,327 shares, reducing both its direct and derivative holdings in NRXS to zero. Because Masimo previously qualified as an “insider” under Section 16 (10% owner), the disposal is considered material. The filing does not give reasons for the divestiture nor mention any concurrent corporate events at Neuraxis.
Barrett Business Services Inc. (BBSI) – Insider Form 4 filing dated 7 July 2025
Director Alexandra Morehouse McReynolds reported the following equity transactions executed on 1 July 2025:
- 3,064 common shares acquired (Transaction Code M) upon the vesting/settlement of an equal number of Restricted Stock Units (RSUs) at an exercise price of $0.00. This increased her direct common-stock holdings to 13,084 shares.
- The underlying RSU position tied to the exercised award was reduced to zero.
- On the same date, the director received a new grant of 2,344 RSUs (Transaction Code A). These RSUs vest in a single tranche on 1 July 2026 and, once vested, will convert 1-for-1 into unrestricted common shares.
No shares were sold and no derivatives were disposed of for cash consideration. All reported equity was acquired at no cost, reflecting scheduled board-compensation awards. After the transactions, Ms. McReynolds holds 13,084 common shares directly and 2,344 RSUs that remain unvested.
The filing signals continued equity alignment between the director and shareholders, but does not, by itself, represent a material corporate event for BBSI.
Neuraxis, Inc. (NRXS) Form 4 filing shows Director and 10% owner Brian P. Hannasch purchased 355,556 common shares on 07/01/2025 at $2.25 per share, an estimated cash outlay of roughly $0.8 million. The transaction was coded “P” (open-market purchase), executed directly, and lifts Hannasch’s total direct holdings to 1,131,522 shares.
Key take-aways:
- The purchase represents a sizable vote of confidence by a control insider.
- Post-transaction ownership exceeds one million shares, reinforcing alignment with minority shareholders.
- No disposals or derivative transactions were reported.
The filing contains no additional financial data or explanatory notes beyond the standard certification.
Schedule 13G/A Amendment 3 highlights that individual investor Brian P. Hannasch now beneficially owns 713,818 shares of Neuraxis, Inc. (NRXS) common stock, representing 7.5 % of the outstanding class as of 30 June 2025. The filing specifies that the position includes 12,852 shares issuable upon exercise of currently exercisable warrants. All voting and dispositive power is held solely by Mr. Hannasch; no shared authority is reported.
The disclosure is filed under Rule 13d-1(c) (passive investor) and is accompanied by the standard certification that the securities were not acquired to influence control. Because ownership exceeds the 5 % threshold, periodic amendments are required; this document is the third amendment to the original Schedule 13G.
Key details for investors
- Beneficial owner: Brian P. Hannasch (U.S. citizen)
- Stake size: 713,818 shares (7.5 % of class)
- Sole voting/dispositive power: 713,818 shares
- No group membership or shared ownership disclosed
- Certification affirms passive investment intent
While the filing does not include financial performance data, it signals that a single investor maintains a sizable, clearly documented position in NRXS, information that may be relevant for tracking insider or significant shareholder activity.
FAQ
What is the current stock price of Neuraxis (NRXS)?
What is the market cap of Neuraxis (NRXS)?
What is the primary focus of Neuraxis Inc?
What technology does Neuraxis Inc utilize in its therapies?
How does Neuraxis Inc support its development process?
Which patient segments does Neuraxis Inc primarily serve?
What distinguishes Neuraxis Inc from competitors in the neuromodulation space?
What are the clinical applications of PENFS technology?
How does Neuraxis Inc ensure the quality of its therapies?
In what ways does Neuraxis Inc demonstrate its expertise and trustworthiness?
